Evidence map›Paper›PMID 26201515›Full record

ArticleThe Biochemical journal2015

Akt kinase C-terminal modifications control activation loop dephosphorylation and enhance insulin response.

Tung O Chan, Jin Zhang, Brian C Tiegs, Brian Blumhof, Linda Yan, Nikhil Keny, Morgan Penny, Xue Li, John M Pascal, Roger S Armen and 2 more

Abstract read
In one paragraph

Article in The Biochemical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. AKT1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Tung O ChanCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Jane and Leonard Korman Lung Center, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. tung.chan@jefferson.edu.
Jin ZhangCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Brian C TiegsCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Brian BlumhofCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Linda YanCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Nikhil KenyCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Morgan PennyCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Xue LiCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
John M PascalKimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Department of Molecular Biology and Biochemistry, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Roger S ArmenDepartment of Pharmaceutical Sciences, School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Ulrich RodeckKimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Raymond B PennCenter for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A. Jane and Leonard Korman Lung Center, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Thomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
G Protein-Coupled Receptor Signaling in Airway Smooth MuR01HL058506 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RAYMOND B. PENN · 2001 to 2026
$9.3M
Optimizing Beta-Adrenoceptor Signaling Bias in AsthmaR01AI110007 · NIAID · DUKE UNIVERSITY · PI BOND, RICHARD AGUSTIN, PENN, RAYMOND B. · 2014 to 2018
$3.2M
BETA ADRENERGIC RECEPTOR REGULATION IN HUMAN AIRWAY MUSCR29HL058506 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI PENN, RAYMOND B. · 1997 to 2000
$113k
NCI NIH HHS P30 CA056036NHLBI NIH HHS HL58506NHLBI NIH HHS R01 HL058506NHLBI NIH HHS R29 HL058506NIAID NIH HHS R01 AI110007
6 · The paper itself

Abstract

The Akt protein kinase, also known as protein kinase B, plays key roles in insulin receptor signalling and regulates cell growth, survival and metabolism. Recently, we described a mechanism to enhance Akt phosphorylation that restricts access of cellular phosphatases to the Akt activation loop (Thr(308) in Akt1 or protein kinase B isoform alpha) in an ATP-dependent manner. In the present paper, we describe a distinct mechanism to control Thr(308) dephosphorylation and thus Akt deactivation that depends on intramolecular interactions of Akt C-terminal sequences with its kinase domain. Modifications of amino acids surrounding the Akt1 C-terminal mTORC2 (mammalian target of rapamycin complex 2) phosphorylation site (Ser(473)) increased phosphatase resistance of the phosphorylated activation loop (pThr(308)) and amplified Akt phosphorylation. Furthermore, the phosphatase-resistant Akt was refractory to ceramide-dependent dephosphorylation and amplified insulin-dependent Thr(308) phosphorylation in a regulated fashion. Collectively, these results suggest that the Akt C-terminal hydrophobic groove is a target for the development of agents that enhance Akt phosphorylation by insulin.

Indexed as

AnimalsCell LineEnzyme ActivationInsulinMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesPhosphorylationProtein Processing, Post-TranslationalProto-Oncogene Proteins c-aktRatsSignal TransductionTOR Serine-Threonine KinasesAkt1 protein, ratInsulinMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesceramidedephosphorylation resistanceinsulin sensitivityprotein kinase Aprotein kinase B/Akt

Identifiers

PMID26201515
PMCPMC4676407
OpenAlexW2142367382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.